Freedom Acquisition I (NASDAQ:FACT – Get Free Report) and Mainz Biomed (NASDAQ:MYNZ – Get Free Report) are both small-cap industrials companies, but which is the better business? We will compare the two companies based on the strength of their risk, valuation, analyst recommendations, institutional ownership, profitability, dividends and earnings.
Institutional and Insider Ownership
55.8% of Freedom Acquisition I shares are held by institutional investors. 0.2% of Freedom Acquisition I shares are held by insiders. Comparatively, 18.2% of Mainz Biomed shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Profitability
This table compares Freedom Acquisition I and Mainz Biomed’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Freedom Acquisition I | N/A | -31.14% | 1.67% |
| Mainz Biomed | N/A | N/A | N/A |
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Freedom Acquisition I | N/A | N/A | $5.98 million | N/A | N/A |
| Mainz Biomed | $659,935.00 | 19.63 | -$21.65 million | ($65.60) | -0.02 |
Freedom Acquisition I has higher earnings, but lower revenue than Mainz Biomed.
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for Freedom Acquisition I and Mainz Biomed, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Freedom Acquisition I | 1 | 0 | 0 | 0 | 1.00 |
| Mainz Biomed | 1 | 1 | 0 | 0 | 1.50 |
Volatility and Risk
Freedom Acquisition I has a beta of 0.01, meaning that its stock price is 99% less volatile than the S&P 500. Comparatively, Mainz Biomed has a beta of 0.31, meaning that its stock price is 69% less volatile than the S&P 500.
Summary
Mainz Biomed beats Freedom Acquisition I on 5 of the 8 factors compared between the two stocks.
About Freedom Acquisition I
Freedom Acquisition I Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or related business combination with one or more businesses. Freedom Acquisition I Corp. was incorporated in 2020 and is based in New York, New York.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.
Receive News & Ratings for Freedom Acquisition I Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Freedom Acquisition I and related companies with MarketBeat.com's FREE daily email newsletter.
-logo-1200x675.jpg){kind=logo}
